Why Analysts See The Myriad Genetics (MYGN) Story Shifting After The New $7 Target

The latest research on Myriad Genetics trims the modeled fair value only slightly, from US$8.32 to US$8.12 per share, and aligns a new US$7 price target with expectations across the broader ...